Comparison of VRS-317 a Long-acting Human Growth Hormone to Daily rhGH in a Phase 3 Randomized One-year Open-label Multi-center Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency. The VELOCITY Study: Versartis Long-Acting Growth Hormone in Children compared to Daily rhGH
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to compare the safety and efficacy of a selected dose regimen of VRS-317 to daily rhGH during 12 months of treatment in children with Growth Hormone Deficiency (GHD).
Description
The purpose of this study is to compare the safety and efficacy of a selected dose regimen of VRS-317 to daily rhGH during 12 months of treatment in children with Growth Hormone Deficiency (GHD).
Details
| Age | 100years or below |
|---|---|
| Clinical Study Identifier | TX4738 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.